NCT05972954

OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)

A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD Patients With Myopathy and/or Cardiomyopathy and Inflammation (PMD-OPTION)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Omeicos Therapeutics GmbH · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about the treatment effects of the investigational new drug OMT-28 in patients with Primary Mitochondrial Disease. The main question\[s\] it aims to answer are: * Is OMT-28 safe and well tolerated in this patient population? * Does OMT-28 reduce Growth Differentiation Factor 15 (GDF-15) and other relevant blood markers of mitochondrial dysfunction and inflammation? * Does OMT-28 improve symptoms of the disease, e.g. fatigue or exercise intolerance? Participants will be asked to participate in 6 study visits at an experienced clinical center, including physical examinations and exercise tests, and take the study medication regularly once per day according to the protocol. Researchers will compare for every participant the results after 3 months and 6 months of treatment with a preceding 3 month period of standard care treatment to investigate the effects of OMT-28 on clinical parameters and a number of blood parameters.

Detailed description

This is an open label, single-arm, multiple-phase and multicenter Phase 2a study to evaluate the efficacy, safety, and pharmacokinetics of a single OMT-28 dose (24 mg given once daily) in patients with Primary Mitochondrial Disease and clinical manifestation of myopathy and/or cardiomyopathy. Patients are eligible if they have * Primary Mitochondrial Disease with a documented mitochondrial transfer ribonucleic acid (tRNA) point mutation, including m3243A\>G, m8344A\>G, or single mitochondrial DNA (mtDNA) deletions, * a clinically relevant myopathy and/or cardiomyopathy confirmed following standard guidelines, * a blood plasma GDF-15 concentration \> 1200 ng/L and \< 10.000 ng/L at screening Participation in the study is divided into 3 parts: * Screening and baseline: 12 weeks * Treatment: 24 weeks * Safety follow-up: 4 weeks Total duration: 40 weeks Safety will be monitored throughout the study. Blood samples for safety, pharmacodynamics and pharmacokinetics will be collected at every of the 6 study visits. Exercise tests (6/12-minutes walking test, 5xSST), transthoracic echocardiography, patient reported outcomes (e.g. Fatigue Severity Scale and Patients' Global Impression of Change (PGIC) scale) will be assessed at prespecified visits. Patients will be provided with a diary to record timing of drug administration and clinical symptoms while not on site. Diaries will be reviewed and checked for compliance at each non-resident visit to the clinical site.

Conditions

• Primary Mitochondrial Disease

Interventions

Type	Name	Description
DRUG	OMT-28	once daily

Timeline

• Start date: 2023-05-22
• Primary completion: 2025-05-14
• Completion: 2025-07-30
• First posted: 2023-08-02
• Last updated: 2026-01-22

Locations

9 sites across 3 countries: Germany, Italy, Netherlands